secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-08-20T20:45:25+00:00
Accession:  0001493152-26-039488
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals appoints James Liddy as director effective August 19, 2026
--------------------------------------------------------------------------------

- Board approved James Liddy as director on August 19, 2026, effective immediately.
- No arrangements or understandings exist with any person regarding Liddy's selection.
- No transactions involving Hepion and Liddy required under Item 404(a) of Reg S-K.
- Form signed by interim CEO Gary Stetz on August 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/0001493152-26-039488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226039488/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer